News Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the ...

Thread starter FeedBot
Start date Dec 23, 2024

Status: Not open for further replies.

FeedBot

Staff member

Dec 23, 2024

NCCN Guidelines for Cervical Cancer now include Puma's neratinib monotherapy for 2nd line or later use in patients with HER2-mutated tumors, Cat.

Continue reading...

Status: Not open for further replies.

Facebook X Bluesky LinkedIn Reddit Pinterest Tumblr WhatsApp Email Link

We value your privacy

We use essential cookies to make this site work, and optional cookies to enhance your experience.

See further information and configure your preferences

Accept all cookies Reject optional cookies
Essential cookies

These cookies are required to enable core functionality such as security, network management, and accessibility. You may not reject these.

Optional cookies

We deliver enhanced functionality for your browsing experience by setting these cookies. If you reject them, enhanced functionality will be unavailable.

Third-party cookies

Cookies set by third parties may be required to power functionality in conjunction with various service providers for security, analytics, performance or advertising purposes.

Detailed cookie usage

Privacy policy

Back

Top Bottom

News Puma Biotechnology&#39;s NERLYNX® Included in NCCN Clinical Practice Guidelines for the ...

FeedBot

We value your privacy

News Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the ...